Alx Oncology Holdings (ALXO) Asset Writedowns and Impairment (2025)

Alx Oncology Holdings' (ALXO) quarterly Asset Writedowns and Impairment came in at $25000.0 in Q3 2025, down 99.22% quarter-over-quarter from $3.2 million in Q2 2025.

Alx Oncology Holdings (ALXO) Asset Writedowns and Impairment (2025) Analysis & Trends

Alx Oncology Holdings has disclosed Asset Writedowns and Impairment across 1 years of filings, most recently posting $25000.0 for Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn -
7 Psyence Biomedical 229.39 Bn 229.38 Bn -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn
9 Abivax 90.15 Bn 90.15 Bn -
10 Alx Oncology Holdings 166.27 Mn 25.95 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2025 25,000.00
Sep 30, 2025 25,000.00
Jun 30, 2025 3.20 Mn
Jun 30, 2025 3.20 Mn